NEW YORK – April 23, 2025

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Professor Dr. Audrey Gabelle, MD, PhD, a specialist of predictive, personalized medicine and digital health in Alzheimer’s disease and related disorders, to the Anavex Scientific Advisory Board.

Dr. Audrey Gabelle is a Professor of Neurology, MD, PhD, Neurologist and Doctor in Neurosciences at the Memory Resources Research Center, the Rare and Early Dementia Reference Center and the European Neurodegenerative Excellence Center of Montpellier University. Dr. Gabelle is also a researcher at the Montpellier Institute of Neurosciences and a member of the European Alzheimer’s Disease Consortium.

Professor Dr. Gabelle is an accomplished leader with 10+ years of experience driving innovation in addition to 10+ years in clinical Phase I–IV trials. She managed 400+ memory centers within the French network. She has a strong publication record with 200+ peer-reviewed scientific papers and is experienced in public-private partnerships and collaborations with pharmaceutical companies. She was a founding member of research projects at both the European and global level and works with international teams.

Professor Dr. Gabelle has expertise in diagnosis, predictive and prognostic biomarkers with the creation of the NeuroCognition biobank in 2007, which includes more than 35,000 samples with CSF, plasma proteomics profiles, and clinical follow-up data. She is involved in major cohorts, including the 3C Study, BALTAZAR, MEMENTO, MAPT, and EPAD, aimed at determining risk stratification and preventive strategies at early stages of neurodegenerative diseases.

Recently, she has focused on real-world evidence (RWE), digital health strategies, and Artificial Intelligence (AI), honed through training at Columbia University, Harvard University Executive Leadership programs, and previous leadership of digital initiatives at Biogen, including the Intuition Study with Apple, published in Nature Medicine.

“I’m thrilled to join Anavex’s Scientific Advisory Board given the convincing profile of blarcamesine as a potentially relevant treatment for patients with Alzheimer’s disease,” said Professor Dr. Gabelle. “There is a tremendous unmet medical need around the globe caused by Alzheimer’s disease. I look forward to collaborating on cutting-edge science and helping guide the development of new therapies that can make a meaningful impact on neurodegenerative disorders. A small molecule administered orally once daily, with demonstrated clinically meaningful improvement and good safety profile, could be a game changer for patients, health care burden, and equity of access to care. I am committed to leveraging my experience and supporting Anavex Life Sciences’ ambition of improving lives through novel precision medicine such as blarcamesine.”

“We are delighted to welcome Professor Dr. Gabelle to Anavex’s Scientific Advisory Board,” stated Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “Professor Dr. Gabelle brings broad expertise in Alzheimer’s disease combined with Digital Health to Anavex. I look forward to her active contributions in advancing blarcamesine (ANAVEX®2-73) to patients diagnosed with Alzheimer’s disease.”

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, CNS diseases, pain, and certain cancers.

Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed a Phase 2a and Phase 2b/3 trial for Alzheimer’s disease, a Phase 2 proof-of-concept study in Parkinson’s disease dementia, and both Phase 2 and Phase 3 studies in adults with Rett syndrome, as well as a Phase 2/3 study in pediatric Rett syndrome patients.

ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies have demonstrated its potential to halt and/or reverse the progression of Alzheimer’s disease. It has also shown anticonvulsant, anti-amnesic, neuroprotective, and antidepressant properties in animal models.

ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical-stage drug candidate demonstrating disease-modifying activity in transgenic Alzheimer’s disease models, addressing cognitive deficits, amyloid, and tau pathologies.

Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical are forward-looking statements based on current expectations and involve risks and uncertainties. Actual results may differ materially due to various factors, including those described in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are qualified by this cautionary statement, and Anavex Life Sciences Corp. undertakes no obligation to update these statements.

For Further Information:

Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Investors:

Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com